Celltrion to expand COVID-19 testing portfolio to include both antigen and antibody testing kits
Celltrion Group today announced plans to expand its diagnostic portfolio for SARS-CoV-2, the virus causing COVID-19, in its efforts to improve access to COVID-19 testing and help prevent the further spread of coronavirus infection worldwide.
Celltrion has completed development of a point-of-care antigen testing (POCT) kit for COVID-19 together with South Korean healthcare company BBB, which specialises in blood testing and lab-on-a-chip technology. The POCT kit is a portable and highly sensitive device for use in rapid point of care testing to support early detection of COVID-19 positive patients in clinical settings.
Promising early results for a prototype of Celltrion’s POCT kit for COVID-19 showed more than 95% sensitivity. The kit uses lab-on-a-chip technology consisting of a microfluidic electrochemical biosensor which aims to give fast and accurate results. The kit is designed to show results within 15-20 minutes, and Celltrion anticipates receiving a CE mark in Europe later this month, ahead of the expected launch in July.
Celltrion has also entered into a distribution agreement with Humasis, a South Korean in-vitro diagnostic company, to distribute and sell a rapid diagnostic test globally this month. This test is a COVID-19 rapid antibody diagnostic test (RDT) kit, which could offer a cost-effective option and can be used by hospitals to confirm patients to be discharged. Celltrion and Humasis will also cooperate in the development of an upgraded rapid antibody diagnostic test and a rapid antigen diagnostic test, for which Celltrion will apply its proprietary COVID-19 antibody-antiviral technology to enhance detection sensitivity. Celltrion plans to leverage its advanced therapeutic technologies to expand the range of co-developed diagnostic devices beyond SARS-CoV-2 to a number of other infectious diseases as it progresses cooperation with Humasis.
“We are keen to drive early diagnosis of COVID-19 through the availability of our testing portfolio,” said Ki-Sung Kwon, Head of R&D Unit at Celltrion. “We have successfully built solid partnerships with local device companies that are prominent in the field of diagnostic testing. We are committed to providing flexibility for testing needs as the pandemic evolves, and are using our expertise and past experience developing antibody treatments and targeting coronaviruses to fight this pandemic.”
In addition to progress in diagnostic methods for COVID-19, Celltrion announced positive pre-clinical results for its antiviral antibody treatment last month.1
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us
Coronaviruses (CoV) are a family of viruses that lead to illnesses from the common cold to severe diseases. Novel coronavirus SARS-CoV-2 is responsible for the disease COVID-19, this new strain, discovered in 2019, is behind the ongoing pandemic outbreak.
The most common signs of COVID-19 include fever, dry cough and tiredness; however, people may also experience other symptoms including shortness of breath and breathing difficulties. Most people infected with the virus will exhibit mild to moderate symptoms however older people, and those with existing underlying conditions such as cardiovascular disease and diabetes are more likely to develop a more severe form of COVID-19.
There are currently no specific vaccines or treatments approved for COVID-19.
Please find up to date information about the outbreak via the World Health Organization at https://www.who.int/health-topics/coronavirus#tab=tab_1
FORWARD LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
1 Celltrion Announces Positive Pre-clinical Results for COVID-19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time [Press Release] Retrieved from https://www.businesswire.com/news/home/20200531005014/en/Celltrion-Announces-Positive-Pre-clinical-Results-COVID--19 Last accessed: June 2020
2 Coronavirus. World Health Organization. Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1 Last accessed: June 2020
3 Coronaviruses. National Institute of Allergy and Infectious Diseases. Available at: https://www.niaid.nih.gov/diseases-conditions/coronaviruses Last accessed: June 2020
For further information please contact:
+44 (0) 7506 339043
+44 (0) 7751 116252
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Moody’s Analytics Wins Two Risk Technology Awards for Stress Testing Solutions15.7.2020 14:00:00 EEST | Press release
Moody’s Analytics has won Enterprise-Wide Stress Testing Product of the Year and Credit Stress-Testing Product of the Year in the 2020 Risk Technology Awards. They’re two of our seven wins in this year’s awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005065/en/ To manage financial risk, banks must understand the potential impacts of different economic scenarios on their credit portfolios. They perform stress tests both to address regulatory requirements and to extract business value from the results, for more informed risk management. Moody’s Analytics solutions help them achieve both goals. Our solutions, including the cloud-based Capital Risk Analyzer, drive stress testing and forecasting programs at banks around the world. Customers make use of the insights gained from stress testing to fulfill regulatory requirements, perform capital planning, and make better and more strategic business decisions. “We’re ho
Brand New Virtual Exhibition in July - Summer Sourcing Weeks丨Go ONLINE15.7.2020 13:07:00 EEST | Press release
The COVID-19 outbreak has put a damper on business activity across the world. With travel limitations in place across markets, it is difficult for international buyers to travel for visiting physical exhibitions. But there is a simple solution – go digital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005405/en/ Brand New Virtual Exhibition in July - Summer Sourcing Weeks | Go ONLINE (Photo: Business Wire) Summer Sourcing Weeks丨Go ONLINE (SSWGO) organised by the Hong Kong Trade Development Council (HKTDC) offers a one-stop sourcing online platform for buyers and suppliers to continue exploring business opportunities in industries including lighting, electronics, ICT, medical & healthcare, houseware, fashion, home textiles & furnishings, gifts & premium as well as printing & packaging. Click2Match is a brand new AI-enabled business matching platform in SSWGO. With tailor-made virtual meeting, meeting planner, live cha
IDEMIA Wins the Security Industry Association (SIA) Award for the Best New Biometric Product for Its VisionPass Advanced Facial Recognition Device15.7.2020 10:00:00 EEST | Press release
IDEMIA, the global leader in Augmented Identity, today announces that VisionPass, its newly launched advanced facial recognition device, won the SIA New Product Showcase Award in the Biometric category, at a virtual ceremony held on July 9th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005029/en/ (Photo: Business Wire) IDEMIA’s team defended the company’s submission in front of the judges by giving a “behind the curtain” overview of why and how IDEMIA developed this product, from a blank sheet of paper, listening to partners’ and clients’ pain points, as well as to their needs in terms of performance, reliability, user experience, etc. The team then explained the technical choices made by its R&D team to meet these very demanding requirements and come up with what is now confirmed with this award, as the most advanced facial recognition terminal on the market. Its 2D+3D+infrared cameras, combined with AI-trained alg
Eaton’s Vehicle Group Leveraging Industry 4.0 Technology to Navigate COVID-19 Pandemic15.7.2020 00:37:00 EEST | Press release
Power management company Eaton today announced its Vehicle Group has been leveraging advanced Industry 4.0 technology to help its global operations safely navigate the ongoing COVID-19 crisis and continue to service its customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714006047/en/ 3D-printed latticed aluminum aerospace parts, which were produced with Laser Powder Bed Fusion on a Concept Laser M2 UP1 3D printer. (Photo: Business Wire) Eaton’s Vehicle Group envisions Industry 4.0 as both operational and informational technologies, enabling autonomous production systems that are connected, optimized, transparent, proactive, and agile. Supported by an integrated ecosystem, the technologies are composed of augmented reality, rapid application development, autonomous robots, digital simulation, and additive manufacturing. “I’m proud of our Vehicle Group team and their ingenuity, especially during the COVID-19 pandemic
PTC Named Global Manufacturing Partner of the Year in the 2020 Microsoft Partner of the Year Awards14.7.2020 21:35:00 EEST | Press release
PTC (NASDAQ: PTC) today announced it has been named the Global Manufacturing Partner of the Year, for the second year in a row, in the Microsoft 2020 Partner of the Year Awards. Honored among a global field of top Microsoft partners, PTC has demonstrated excellence in innovation and implementation of customer solutions based on Microsoft technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005951/en/ Honored among a global field of top Microsoft partners, PTC has demonstrated excellence in innovation and implementation of customer solutions based on Microsoft technology. “We are pleased to announce that PTC has been recognized by Microsoft as the Global Manufacturing Partner of the Year for the second consecutive year,” said Jim Heppelmann, President and CEO, PTC. “Together, PTC and Microsoft have enabled digital transformation for some of the world’s largest organizations. We look forward to continuing that succ
Spotify Launches in Russia and 12 Additional European Markets14.7.2020 20:30:00 EEST | Press release
Spotify (NYSE: SPOT) today launched its service in 13 new markets across Europe including Russia, one of the world’s top 20 largest streaming markets. Already the world’s most popular audio streaming subscription service, with today’s expansion, Spotify now reaches a current total of 92 markets worldwide. Spotify’s 13 new markets include: Albania, Belarus, Bosnia & Herzegovina, Croatia, Kazakhstan, Kosovo, Moldova, Montenegro, North Macedonia, Russia, Serbia, Slovenia, Ukraine. As the leading platform driving music discovery on more types of devices than any other service, Spotify’s expansion in Europe comes as consumers in the region embrace streaming. According to the International Federation of the Phonographic Industry (IFPI), Russia is the 17th-biggest streaming market in the world and on pace to be the 10th-biggest streaming market by 2030. More than 87 percent of fans in Russia now access music through streaming, compared to 61 percent adoption globally, and 68 percent adoption
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom